OncoMatch/Clinical Trials/NCT05188508
Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
Is NCT05188508 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Pembrolizumab and Olaparib and Temozolomide for glioma.
Treatment: Pembrolizumab · Olaparib and Temozolomide — This study will test the safety and effectiveness of a combination of pembrolizumab, olaparib, and temozolomide to see how well these drugs work when given together in people with a glioma that either did not respond to previous treatment or came back after treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Required: ATM deleterious mutation
Required: BARD1 deleterious mutation
Required: BRCA1 deleterious mutation
Required: BRCA2 deleterious mutation
Required: BRIP1 deleterious mutation
Required: CDK12 deleterious mutation
Required: CDKN2A wild-type
Required: CDKN2B wild-type
Required: CHEK1 deleterious mutation
Required: CHEK2 deleterious mutation
Required: FANCL deleterious mutation
Required: IDH1 mutation
Required: IDH1 wild-type
Required: PALB2 deleterious mutation
Required: PPP2R2A deleterious mutation
Required: RAD51B deleterious mutation
Required: RAD51C deleterious mutation
Required: RAD51D deleterious mutation
Required: RAD54L deleterious mutation
Disease stage
Required: Stage II, III
Grade: iiiii
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: surgical resection
Cannot have received: any investigational or standard anti-tumor therapy
Lab requirements
Blood counts
absolute neutrophil count (anc) ≥1500/μl platelets ≥100 000/μl hemoglobin ≥9.0 g/dl or ≥5.6 mmol/l
Kidney function
creatinine or measured or calculated creatinine clearance (gfr can also be used in place of creatinine or crcl) ≤1.5 × uln or ≥30 ml/min for participant with creatinine levels <1.5 × institutional uln
Liver function
total bilirubin ≤1.5 ×uln or direct bilirubin ≤uln for participants with total bilirubin levels >1.5 × uln ast (sgot) and alt (sgpt) ≤2.5 × uln (≤5 × uln for participants with liver metastases)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Hartford Healthcare Alliance (Data Collection Only) · Hartford, Connecticut
- BAPTIST ALLIANCE - MCI (Data Collection Only) · Miami, Florida
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify